Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00478439 · ClinicalTrials.gov registry record · Phase 4
Investigation of Macular Pigment Augmentation on Dark Adaptation
A Phase 4 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
NCT00478439: Clinical Trial Phase 4 study, sponsored by University of Alabama at Birmingham.
NCT00478439 is a Phase 4 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 13 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00478439, a Phase 4 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
Study Summary
The study will evaluate whether taking a nutritional supplement designed to increase macular pigment in the eye can improve a person's ability to adjust to darkness. Patients will be assigned to take either a placebo or nutritional supplement for 8 months. Vision will be assessed at baseline, 4 months, and 8 months.
Interventions
- DIETARY_SUPPLEMENT Multivitamin
- DIETARY_SUPPLEMENT ZeaVision EyePromise Restore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-10 |
| Phase | Phase 4 |
Why NCT00478439 stopped before completion
NCT00478439 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Multivitamin is the first listed.
NCT00478439 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00478439 about?
NCT00478439 is a clinical study titled "Investigation of Macular Pigment Augmentation on Dark Adaptation". The study will evaluate whether taking a nutritional supplement designed to increase macular pigment in the eye can improve a person's ability to adjust to darkness. Patients will be assigned to take either a placebo or nutritional supplement for 8 months. Vision will be assessed at baseline, 4 mont...
What is the current status of trial NCT00478439?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2007-12. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00478439?
The interventions under investigation include: Multivitamin (DIETARY_SUPPLEMENT), ZeaVision EyePromise Restore (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00478439?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00478439's enrollment target sits among peer trials
13 1910th of 2000 higher than 88 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia